Online BPC-157 dosage charts by weight trace back to rat studies and a scaling formula built for something else. Here is what the classic 10 µg/kg rat dose converts to, what the few human studies actually gave people, and why no validated human dose exists yet.
If you have been searching for a BPC-157 dosage chart by weight, you are looking for something that does not exist in the medical literature. No regulator has approved BPC-157, no Phase II trial has been completed, and a 2026 review in Pharmaceutics states plainly that there is "no validated dosing regimen" (doi.org/10.3390/pharmaceutics18050625). What does exist is a set of rat studies that dosed BPC-157 per kilogram of body weight, a standard formula for translating animal doses into human equivalents, and a small number of human pilot studies that used fixed milligram amounts.
This article puts those three things side by side. You will see what the classic rat dose works out to when it is run through body surface area scaling, why that number is a calculation rather than a dose, and what the human studies actually gave people. If you are new to the peptide, our guide BPC-157: A Women's Guide explains the gut and healing research in plain terms. This is educational content about published research, and it is neither medical advice nor a dosing recommendation.
Key takeaways
Is there a validated human dose?
No. A 2026 Pharmaceutics review reports no approved formulation, no validated dosing regimen and no completed Phase II trial.
Where per kg doses come from
Rat studies that gave 10 µg/kg or 10 ng/kg, two doses 1,000 times apart, both reported as active.
Rat to human scaling
Body surface area scaling multiplies a rat dose by 0.162, so 10 µg/kg in a rat is about 1.62 µg/kg in a person. The method is not supported for subcutaneous or intramuscular routes.
What human studies used
Fixed amounts: 2 to 4 mg into the knee, 10 mg into the bladder wall, and 10 mg then 20 mg by IV infusion, in very small uncontrolled groups.
Is it a GLP-1?
No. The FDA describes BPC-157 as a 15 amino acid fragment of a protein from human gastric juice, and no trial has tested it for weight loss.
Sources: Mateescu and colleagues, Pharmaceutics, 2026; Sikiric and colleagues, European Journal of Pharmacology, 1997; Nair and Jacob, Journal of Basic and Clinical Pharmacy, 2016; FDA PCAC briefing document, 2026.
There is no official BPC-157 dosage chart by weight, because no regulator has approved BPC-157 for any use and no clinical trial has established a dose in humans. Every weight based chart you find online is either a conversion of animal doses or a vendor's estimate.
The evidence gap is documented from several directions. A 2025 systematic review in the HSS Journal by Vasireddi and colleagues screened 544 articles published from 1993 to 2024 and included 36 studies, of which 35 were preclinical and 1 was clinical, and the authors reported that "no clinical safety data were found" (doi.org/10.1177/15563316251355551). A 2026 narrative review in Pharmaceutics by Mateescu and colleagues concluded that the available clinical data come from fewer than 30 subjects across three uncontrolled pilot studies. A 2026 primer for orthopaedic surgeons in the American Journal of Sports Medicine by Mayfield and colleagues went further, stating that "information regarding the indications, dosing, frequency, and duration of treatment remains unknown" (doi.org/10.1177/03635465251357593).
The FDA reached the same place in its briefing document for the July 23 to 24, 2026 meeting of its Pharmacy Compounding Advisory Committee, where the agency concluded that there is "insufficient clinical safety information to characterize the safety profile" of BPC-157 (fda.gov/media/193343/download).
BPC-157 doses written per kilogram come from rat studies, run mostly by the Zagreb group that first described the peptide in 1993. Those studies typically gave BPC-157 at 10 µg/kg or 10 ng/kg, usually by injection into the abdomen or a vein.
A representative example is the 1997 study by Sikiric and colleagues in the European Journal of Pharmacology, which tested BPC-157 at "10 microg or 10 ng/kg" against stomach lesions and drug induced blood pressure changes in rats (doi.org/10.1016/s0014-2999(97)01033-9). The detail worth noticing is the spread between those two doses. A microgram is 1,000 nanograms, so the two doses sit 1,000 times apart, and the group reported activity at both. In ordinary drug development, a compound that still works at a thousandth of the amount would be a puzzle to solve before anyone wrote a human dosing table, yet for BPC-157 that range has simply been carried forward into online charts. We looked at what the same 1997 study found on blood pressure in Does BPC-157 Lower Blood Pressure? What the Rat, Artery and Human Data Actually Show.
The pharmacokinetics add a second puzzle. A 2022 study by He and colleagues in Frontiers in Pharmacology measured how BPC-157 moves through rats and beagle dogs, and found that the elimination half life of intact BPC-157 was under 30 minutes, that its kinetics were linear across doses, and that absolute bioavailability after intramuscular injection was approximately 14% to 19% in rats and 45% to 51% in dogs (doi.org/10.3389/fphar.2022.1026182). The 2026 Pharmaceutics review describes the contrast between a half life of under 30 minutes and biological effects "lasting hours to days" as a disconnect with "significant implications for dosing strategy." Put simply, nobody yet knows what blood level, if any, a dose is supposed to reach.
"The two classic rat doses of BPC-157 sit 1,000 times apart, and both were reported as active, which is a range no weight chart can narrow."
Absolute bioavailability of BPC-157 after intramuscular injection (%)
Reported ranges were approximately 14% to 19% in rats and 45% to 51% in beagle dogs, with an elimination half life under 30 minutes in both species. No equivalent human data exist. Source: He and colleagues, Frontiers in Pharmacology, 2022.
Researchers convert an animal dose to a human equivalent dose (HED) by scaling for body surface area rather than body weight, because smaller animals burn energy and clear drugs faster per kilogram. The method comes from FDA guidance on starting doses for first in human trials, and a widely cited 2016 practice guide by Nair and Jacob in the Journal of Basic and Clinical Pharmacy summarizes it (doi.org/10.4103/0976-0105.177703).
The formula uses a correction factor called Km for each species. For a reference human of 60 kg with a body surface area of 1.62 m², Km is 37, and for a standard rat Km is 6. The guide gives the shortcut directly: "the K m ratio values for rat is 6.2 and 0.162." To get a human equivalent dose in mg/kg, you multiply the rat dose by 0.162, which is the same as dividing it by 6.2.
Two caveats from the same guide matter more than the arithmetic. The method was built to estimate a safe starting dose from the highest dose that caused no adverse effects in animals, and the next step in that process is to divide the result by a safety factor of 10, so it was never meant to turn an animal efficacy dose into a treatment dose. The guide also states that conversion based on body surface area "is not supported for drugs administered by topical, nasal, subcutaneous, or intramuscular routes," and subcutaneous injection is the route most people asking about BPC-157 have in mind.
Run through body surface area scaling, the classic rat dose of 10 µg/kg works out to a human equivalent of about 1.62 µg/kg. Multiplied by body weight, that comes to roughly 81 µg for a 50 kg (110 lb) adult and 162 µg for a 100 kg (220 lb) adult, as the chart and table below show. These figures are a calculation from rat data rather than a dose, and they inherit every limitation described above.
Calculated: the 10 µg/kg rat dose converted by body weight (µg)
Calculated by PeptidePeppers: rat dose of 10 µg/kg (Sikiric and colleagues, 1997) multiplied by the rat to human Km ratio of 0.162 (Nair and Jacob, 2016), then by body weight. This is unit conversion from animal data, not a recommended or validated dose, and the scaling method is not supported for subcutaneous or intramuscular use.
Rat doses converted to human equivalents by body weight
| Body weight | From 10 µg/kg rat dose (1.62 µg/kg) | From 10 ng/kg rat dose (1.62 ng/kg) | After the ÷10 safety factor (µg column) |
|---|---|---|---|
| 50 kg (110 lb) | 81 µg | 81 ng | 8.1 µg |
| 60 kg (132 lb) | 97.2 µg | 97.2 ng | 9.7 µg |
| 70 kg (154 lb) | 113.4 µg | 113.4 ng | 11.3 µg |
| 80 kg (176 lb) | 129.6 µg | 129.6 ng | 13 µg |
| 90 kg (198 lb) | 145.8 µg | 145.8 ng | 14.6 µg |
| 100 kg (220 lb) | 162 µg | 162 ng | 16.2 µg |
Calculated by PeptidePeppers from the rat doses in Sikiric and colleagues (1997) and the Km ratio of 0.162 in Nair and Jacob (2016). This is unit conversion, not a recommended or validated dose.
Three things stand out when you look at the table. The two columns differ 1,000 times over, and the rat literature gives no way to choose between them. The scaling method itself is not supported for injection under the skin or into muscle. Finally, the human pilot studies described below used amounts in the milligram range, far above either column, which shows that the clinicians running those studies were not working from this conversion either.
Most human studies of BPC-157 have used fixed doses in milligrams rather than doses scaled to body weight, and the one weight based exposure the FDA lists was up to 2 mg/kg by rectal enema once daily for 8 days in 24 healthy subjects. The FDA's 2026 briefing document found five clinical studies in PubMed and Embase and summarized how BPC-157 was given in each, as shown in the table below.
The agency's assessment of this evidence was blunt: "these studies were of short duration, had small sample sizes, evaluated doses that were likely exploratory in nature, and the authors provided limited information on safety data." The three recent pilot studies by Lee and colleagues had no control or placebo group, which is why the 2026 Pharmaceutics review describes them as three uncontrolled pilot studies. The knee study by Lee and Padgett (2021) was a retrospective chart review in which 11 of 12 patients who received BPC-157 alone (91.6%) reported significant improvement, with no control group and no standardized outcome measures (pubmed.ncbi.nlm.nih.gov/34324435). The bladder study by Lee, Walker and Ayadi (2024) enrolled 12 women aged 39 to 76 and gave a total of 10 mg in one procedure, again without a comparison group (pubmed.ncbi.nlm.nih.gov/39325560). The IV pilot by Lee and Burgess (2025) involved two people, a 58 year old man and a 68 year old woman, who received 10 mg and then 20 mg in 250 cc of saline, and the authors reported no side effects (pubmed.ncbi.nlm.nih.gov/40131143).
The FDA also found a single registered phase 1 trial of oral BPC-157 tablets (NCT02637284) that planned single doses of 1 mg, 3 mg or 6 mg, followed by 3 mg every 8 hours for 2 weeks, with an estimated enrollment of 42. No results have been posted or published, and the agency found "no human pharmacokinetic data for BPC-157 after oral, SC, nasal, or transdermal administration."
Doses given in the five human BPC-157 studies the FDA identified
| Study | Route | Dose | People |
|---|---|---|---|
| Healthy volunteers (enema meeting abstracts) | Rectal enema, once daily for 8 days | Up to 2 mg/kg | 24 |
| Ulcerative colitis (enema study) | Rectal enema, once daily for 2 weeks | 80 mg | About 26 |
| Knee pain chart review (Lee and Padgett, 2021) | Injection into the knee joint, 1 to 2 doses | 2 to 4 mg | 17 |
| Interstitial cystitis pilot (Lee, Walker and Ayadi, 2024) | Injection into the bladder wall, single procedure | 10 mg total | 12 |
| IV safety pilot (Lee and Burgess, 2025) | IV infusion over one hour | 10 mg on day 1, 20 mg on day 2 | 2 |
The three Lee pilot studies had no control or placebo group, and the FDA described the doses as likely exploratory. Source: FDA PCAC briefing document, July 2026.
How many people sit behind each human BPC-157 dose
The colitis enema study enrolled about 26 people. The oral phase 1 trial (NCT02637284) had an estimated enrollment of 42 and has no posted or published results. Source: FDA PCAC briefing document, 2026.
Dosing by weight requires knowing how a drug's exposure scales with body size and which exposure produces a benefit without harm, and for BPC-157 none of those pieces have been measured in people.
Each link in that chain is missing. Because there is no human pharmacokinetic data for subcutaneous use, nobody knows how much of an injected dose reaches your blood. The animal data show a 1,000 times range of active doses rather than a dose response curve. The half life is under 30 minutes in animals while the reported effects last far longer, so plasma levels may not even be the right target, and the human exposures were mostly fixed milligram amounts, apart from one enema study that gave up to 2 mg/kg, in groups of 2 to 26 people.
There is also a product problem that no chart can fix. The FDA's briefing raised concerns about peptide related impurities and aggregation, and it noted that "as a peptide with 15 amino acids that is administered through a parenteral or nasal ROA, BPC-157 may pose a significant risk for immunogenicity," meaning your immune system could react to it. The Vasireddi review likewise warned that adverse effects are possible "due to unregulated manufacturing, contamination, or unknown clinical safety." When the content of a vial is uncertain, the number printed on a dosing chart is not the dose you actually receive.
"When the content of a vial is uncertain, the number printed on a dosing chart is not the dose you actually receive."
BPC-157 is not a GLP-1 and does not act like one. The FDA describes BPC-157 as "a pentadecapeptide fragment of the BPC protein originally isolated from human gastric juice." GLP-1 medicines such as semaglutide and tirzepatide are designed to act on hormone receptors that regulate appetite and blood sugar, and BPC-157 has no established action on those receptors.
The confusion probably comes from the gut, since both BPC-157 and GLP-1 have origins in the digestive system and both are injectable peptides sold through some of the same clinics. That is where the similarity ends. For a look at how GLP-1 medicines act on the brain, see our article Why Do GLP-1 Drugs Reduce Alcohol Cravings?
There is no clinical evidence that BPC-157 helps with weight loss. None of the five human studies the FDA identified measured body weight as an outcome, and the 2025 systematic review found only one clinical study of any kind in the musculoskeletal literature.
BPC-157 is studied and marketed mainly for tissue repair in tendons, ligaments, muscle and the gut lining, so any weight loss claim attached to BPC-157 is not established in trials.
In research, BPC-157 is studied mainly for healing of the gut, tendons, ligaments, muscle and bone, almost entirely in rats. The 2025 HSS Journal systematic review found that in preclinical models BPC-157 "improved functional, structural, and biomechanical outcomes in muscle, tendon, ligament, and bony injuries," and that it appears to influence growth hormone receptor expression, blood vessel growth and inflammatory signaling.
The same review notes that BPC-157 lacks FDA approval and that its use is banned in professional sports. The 2026 sports medicine primer reached a similar verdict on recovery peptides as a group, describing their benefits as largely unvalidated in human trials. Our review BPC-157 and TB-500 Together: What the Research Actually Shows About the Wolverine Stack covers that evidence in more detail.
A BPC-157 dosage chart by weight can only ever be a conversion of rat doses, and the conversion method itself is not supported for the injection routes people actually use. The rat doses span a 1,000 times range, the human studies used fixed milligram amounts in tiny uncontrolled groups, and the FDA has said there is not enough clinical safety information to characterize BPC-157 at all. If you are considering any peptide, the honest starting point is a clinician who knows what you are taking and can monitor you, because the dose that is right for you has simply not been worked out by research yet.
Sikiric P, et al. The influence of a novel pentadecapeptide, BPC 157, on NG nitro L-arginine methylester and L-arginine effects on stomach mucosa integrity and blood pressure. European Journal of Pharmacology, 1997. doi.org/10.1016/s0014-2999(97)01033-9
Nair AB, Jacob S. A simple practice guide for dose conversion between animals and human. Journal of Basic and Clinical Pharmacy, 2016. doi.org/10.4103/0976-0105.177703
He L, et al. Pharmacokinetics, distribution, metabolism, and excretion of body protective compound 157, a potential drug for treating various wounds, in rats and dogs. Frontiers in Pharmacology, 2022. doi.org/10.3389/fphar.2022.1026182
Lee E, Padgett B. Intra articular injection of BPC 157 for multiple types of knee pain. Alternative Therapies in Health and Medicine, 2021. pubmed.ncbi.nlm.nih.gov/34324435
Lee E, Walker C, Ayadi B. Effect of BPC-157 on symptoms in patients with interstitial cystitis: a pilot study. Alternative Therapies in Health and Medicine, 2024. pubmed.ncbi.nlm.nih.gov/39325560
Lee E, Burgess K. Safety of intravenous infusion of BPC157 in humans: a pilot study. Alternative Therapies in Health and Medicine, 2025. pubmed.ncbi.nlm.nih.gov/40131143
Vasireddi N, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS Journal, 2025. doi.org/10.1177/15563316251355551
Mateescu DM, et al. BPC-157 as an investigational peptide therapeutic: biopharmaceutical challenges, formulation strategies, and translational development barriers. Pharmaceutics, 2026. doi.org/10.3390/pharmaceutics18050625
Mayfield CK, et al. Injectable peptide therapy: a primer for orthopaedic and sports medicine physicians. American Journal of Sports Medicine, 2026. doi.org/10.1177/03635465251357593
U.S. Food and Drug Administration. FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting, July 23 and 24, 2026: BPC-157 related bulk drug substances. fda.gov/media/193343/download
The classic rat studies gave BPC-157 at 10 µg/kg or 10 ng/kg, usually by injection. Both doses were reported as active even though they sit 1,000 times apart. These are animal doses, and none of them has been validated in people.
Using standard body surface area scaling, a 10 µg/kg rat dose corresponds to about 1.62 µg/kg in humans, or roughly 113.4 µg for a 70 kg adult. That figure is a unit conversion rather than a dose. The method guide behind the formula says body surface area conversion is not supported for subcutaneous or intramuscular routes, and starting doses in trials are usually divided by a further safety factor of 10.
The recent pilot studies used fixed amounts: 2 to 4 mg injected into the knee, 10 mg injected around the bladder, and 10 mg followed by 20 mg by IV infusion. Two earlier enema studies gave up to 2 mg/kg daily for 8 days to 24 healthy subjects and 80 mg daily for 2 weeks to about 26 people with ulcerative colitis. Groups ranged from 2 to about 26 people, the recent pilot studies had no placebo group, and the FDA described the doses as likely exploratory in nature.
There is no FDA approved dose of BPC-157, because the FDA has not approved BPC-157 for any use. The FDA's 2026 briefing document concluded that there is insufficient clinical safety information to characterize the safety profile of BPC-157.
Microgram figures online usually come from converting the 10 µg/kg rat dose by body weight. The published human pilot studies used milligram amounts instead, so the two sources do not agree, which is itself a sign that no tested dosing framework exists for BPC-157.
In rats and dogs, intact BPC-157 has an elimination half life of under 30 minutes, according to a 2022 pharmacokinetic study in Frontiers in Pharmacology. The FDA found no human pharmacokinetic data for oral, subcutaneous, nasal or transdermal use, so how long BPC-157 lasts in people is not established.
BPC-157 is not a GLP-1 agonist. It is a 15 amino acid fragment of a protein found in human gastric juice, and it has no established action on GLP-1 receptors. BPC-157 is studied for tissue repair rather than for appetite or blood sugar.
No clinical study has tested BPC-157 for weight loss, and none of the human studies the FDA reviewed measured body weight. Weight loss claims made for BPC-157 are not supported by trial evidence.
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before beginning any peptide protocol.
About this post
Related reading